Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Cash & Equivalents (2016 - 2025)

Immucell's Cash & Equivalents history spans 16 years, with the latest figure at $3.8 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 1.29% year-over-year to $3.8 million; the TTM value through Dec 2025 reached $3.8 million, up 1.29%, while the annual FY2025 figure was $3.8 million, 1.29% up from the prior year.
  • Cash & Equivalents reached $3.8 million in Q4 2025 per ICCC's latest filing, down from $3.9 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $11.8 million in Q1 2022 to a low of $960347.0 in Q1 2024.
  • Average Cash & Equivalents over 5 years is $5.6 million, with a median of $4.2 million recorded in 2025.
  • Peak YoY movement for Cash & Equivalents: crashed 86.83% in 2023, then skyrocketed 378.93% in 2025.
  • A 5-year view of Cash & Equivalents shows it stood at $10.2 million in 2021, then tumbled by 43.14% to $5.8 million in 2022, then tumbled by 83.1% to $978741.0 in 2023, then skyrocketed by 283.99% to $3.8 million in 2024, then grew by 1.29% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Cash & Equivalents are $3.8 million (Q4 2025), $3.9 million (Q3 2025), and $6.0 million (Q2 2025).